Riboscience to Present First Overall Survival and Immune Activation Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination in Advanced Metastatic Cancers Including MSS CRC, at ESMO 2026 - Morningstar
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
PALO ALTO, Calif., Oct. 19, 2026 /PRNewswire/ -- Riboscience, a clinical-stage biotechnology company developing first-in-class immunotherapies, today announced that Phase 1b data for RBS2418, its lead oral ENPP1 inhibitor, will be presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026, held October 23–27 in Madrid, Spain.
Title: Overall survival and intratumoral immune activation in subjects with advanced metastatic solid tumors, by Thomas U. Marron, Jamal G. Misleh, Michael Gordon, Zev A. Wainberg, Christopher T. Chen, Daniel Johnson, Alexander I. Spira, Jordan Berlin, Won Jin Ho, John T. Hamm, Ralph V. Boccia, Seol Hee Im, Stephan Rogalla, Juergen Schanzer, Ningwu Huang, Sayantanee Paul, Edward Pham, Buer Song, Jeffrey S. Glenn, Hirak Der-Torossian, Klaus Klumpp and Aaron J. Scott
This article is an excerpt. To read the full content, visit the original source. Morningstar
Related articles
Real-World Outcomes After Selective RET Inhibitor Failure in Metastatic Lung Cancer - Oncodaily
A new study published in Clinical Cancer Research Title: Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry
Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations - HCPLive
Chronic proton pump inhibitor use carried 60% greater odds of asthma exacerbation and nearly 4-fold odds of rescue corticosteroid use in a matched cohort of 2456 patients.
Western University - Marginalized patients have increased risk of early death from newly diagnosed metastatic breast cancer, study finds - Education News Canada
People who are marginalized or lack access to a primary care provider are at greater risk of early death from newly diagnosed metastatic breast cancer, according to research in CMAJ (Canadian Medical Association Journal). The Ontario study found nearly one-quarter of people with stage four metastasized breast cancer that has already spread to other sites in the body when it is found - also known as de novo breast cancer - died within six months of diagnosis.
Retifanlimab Versus Avelumab for Metastatic Merkel Cell Carcinoma: Comparative Analysis Insights - DocWireNews
Results from a recent matching-adjusted indirect comparison (MAIC) analysis indicated clinical favorability of retifanlimab versus avelumab for the treatment of metastatic Merkel cell carcinoma (MCC), which investigators described as “a rare and aggressive skin cancer with poor prognosis and low survival rate. A team of researchers from Italy conducted the study and published their findings in Advances in Therapy. Both retifanlimab and avelumab are classified as monoclonal immune checkpoint inhibitor (ICI) antibodies, and investigators highlighted that both medications are approved for the treatment of metastatic or locally advanced recurrent MCC. They explained that the goal of their research was to assess clinical outcomes of both ICIs via a MAIC analysis of data from the phase 2 POD1UM-201 trial and part B of the phase 2 JAVELIN Merkel 200 trial. Patient data from each trial were used in the analysis, with data from POD1UM-201 informing the retifanlimab group and aggregate data from JAVELIN Merkel 200 informing the avelumab treatment group. Investigators also underscored that the data cutoff of POD1UM-201 was July 2024.
0 comments
No comments yet. Be the first to share your thoughts!